ReviewClinical and molecular allergy : CMA2016
Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay.
Review in Clinical and molecular allergy : CMA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 48 citations in OpenAlex.
- Review
- Epigenetic regulation of thrombo-inflammation in Behçet and antiphospholipid syndrome.Journal of translational autoimmunity · 2025Article
- Antiphospholipid antibody positivity is associated with maturation failure and thrombosis of native arteriovenous fistula: a retrospective study in HD patients.Clinical kidney journal · 2024Article
- Antiphospholipid antibodies in patients with antiphospholipid syndrome.Biochemia medica · 2024Review
- Positive antiphospholipid antibodies: observation or treatment?Journal of thrombosis and thrombolysis · 2023Review
- Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d.Frontiers in immunology · 2022Article
- Thrombin generation assays to personalize treatment in bleeding and thrombotic diseases.Frontiers in cardiovascular medicine · 2022Review
- Clinical use of thrombin generation assays.Journal of thrombosis and haemostasis : JTH · 2021Review
- Oxidative Stress in the Pathogenesis of Antiphospholipid Syndrome: Implications for the Atherothrombotic Process.Antioxidants (Basel, Switzerland) · 2021Review
- Thrombotic risk in antiphospholipidic syndrome: From hypothesis to current evidence (Review).Experimental and therapeutic medicine · 2021Review
- Hemocoagulative post-operative changes after laparoscopic surgery compared to open surgery: the role of lupus anticoagulant.Updates in surgery · 2020Article
- Anti-domain 1 β2 glycoprotein antibodies increase expression of tissue factor on monocytes and activate NK Cells and CD8+ cells in vitro.Auto- immunity highlights · 2020Article
- Shear stress-exposed pulmonary artery endothelial cells fail to upregulate HSP70 in chronic thromboembolic pulmonary hypertension.PloS one · 2020Article
- Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?Current rheumatology reports · 2018Review
- Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin.Blood advances · 2018Article
- An Uncommon Case of Lower Limb Deep Vein Thrombosis with Multiple Etiological Causes.The American journal of case reports · 2017Article
- Neurological and Neurosurgical Emergencies in Patients with Hematological Disorders.Current neurology and neuroscience reports · 2017Review
- Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome.Internal and emergency medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is an autoimmune condition characterized by the presence of antiphospholipid antibodies (aPL) in subjects presenting with thrombosis and/or pregnancy loss. The currently used classification criteria were updated in the international consensus held in Sidney in 2005. Vascular events seem to result of local procoagulative alterations upon triggers influence (the so called "second-hit theory"), while placental thrombosis and complement activation seem to lead to pregnancy morbidity. The laboratory tests suggested by the current classification criteria include lupus anticoagulant, a functional coagulation assay, and anticardiolipin and anti-β2-glycoprotein-I antibodies, generally detected by solid phase enzyme-linked immunosorbent assay. The real challenge for treating physicians is understanding what is the actual weight of aPL in provoking clinical manifestations in each case. As thrombosis has a multi-factorial cause, each patient needs a risk-stratified approach. In this review we discuss the role of thrombotic risk assessment in primary and secondary prevention of venous and arterial thromboembolic disease in patients with APS, focusing on new antibody specificities, available risk scoring models and new coagulation assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.